Lyell Immunopharma (LYEL) EBIT (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of EBIT data on file, last reported at -$44.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 22.85% year-over-year to -$44.3 million; the trailing twelve-month figure through Mar 2026 stood at -$256.3 million (up 28.91% YoY), and the FY2025 full-year result was -$269.4 million, up 24.91% from the prior year.
• EBIT advanced to -$44.3 million in Q1 2026, from -$127.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$14.8 million in Q4 2022 to a low of -$201.1 million in Q4 2024.
• A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 68.9% in 2022 and slumped 302.52% in 2023, its largest moves.
• Tracing LYEL's EBIT over 5 years: stood at -$14.8 million in 2022, then tumbled by 302.52% to -$59.5 million in 2023, then sank by 238.02% to -$201.1 million in 2024, then soared by 36.54% to -$127.6 million in 2025, then surged by 65.32% to -$44.3 million in 2026.
• Business Quant data shows LYEL's EBIT at -$44.3 million in Q1 2026, -$127.6 million in Q4 2025, and -$37.3 million in Q3 2025.